ArriVent BioPharma Reports Third Quarter 2026 Financial Results
Key Highlights
- ➤FURVENT missed its primary PFS endpoint in Phase 3.
- ➤ARR-217 showed 44.8% ORR and 93.1% disease-control rate at 6 mg/kg.
- ➤ALPACCA Phase 3 enrollment remains on track for PACC-mutant NSCLC.
- ➤Cash and investments totaled $393.2 million, funding operations to mid-2028.
- ➤ARR-002 dosed its first U.S. Phase 1a/1b patient.
Expert Statements
Bing Yao, CEO of ArriVent BioPharma
“Enrollment remains on track for our global Phase 3 ALPACCA trial in first line EGFR PACC mutant NSCLC patients. While FURVENT did not meet its primary endpoint, firmonertinib demonstrated clear antitumor activity, with an efficacy and safety profile consistent with prior studies. We are conducting a detailed review of the FURVENT study to better understand the totality of the data.”
Bing Yao, CEO of ArriVent BioPharma
“Our antibody-drug conjugate (ADC) portfolio is also advancing, with initial ARR-217 data showing promising antitumor activity and a manageable safety profile in colorectal cancer. In addition, we dosed the first patient in a Phase 1 study of ARR-002. We are encouraged by the momentum across our pipeline and excited about the opportunity to advance these programs toward new potential treatment options for patients with significant unmet needs.”
Bing Yao, CEO of ArriVent BioPharma
“Dr. Lutzker has been the driving force behind our R&D vision. We are deeply grateful for his unwavering commitment and passion in advancing new therapies for patients. We thank him for all his contributions.”
* Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLC * Presented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMO * Dosed first patient in U.S. Phase 1a/1b study of ARR-002, a novel dual-target MUC16/NaPi2b tetravalent ADC, with initial focus in ovarian and endometrial cancers * Strengthened clinical leadership with announcement of Priti Patel, M.D., M.S., as Chief Medical Officer, bringing extensive oncology development experience * Cash and investments of $393.2 million as of September 30, 2026 expected to fund operations to mid-2028 NEWTOWN SQUARE, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the third quarter ended September 30, 2026, and highlighted recent Company progress.
Get started
Create a free account to read the full story.